Sharad Purohit

List of Publications by Year
in descending order

47 papers	1,586 citations	331259 21 h-index	301761 39 g-index
53 all docs	53 docs citations	53 times ranked	2583 citing authors

#	Article	IF	Citations
1	Emerging urinary alpha-synuclein and miRNA biomarkers in Parkinsonâ€™s disease. Metabolic Brain Disease, 2022, 37, 1687-1696.	1.4	4
2	Multiplex Glycan Bead Array (MGBA) for High Throughput and High Content Analyses of Glycan-Binding Proteins Including Natural Anti-Glycan Antibodies. Methods in Molecular Biology, 2022, 2460, 33-44.	0.4	1
3	Oncocytoma-Related Gene Signature to Differentiate Chromophobe Renal Cancer and Oncocytoma Using Machine Learning. Cells, 2022, 11, 287.	1.8	5
4	Development of a Single Molecule Counting Assay to Differentiate Chromophobe Renal Cancer and Oncocytoma in Clinics. Cancers, 2022, 14, 3242.	1.7	2
5	Retrospective Validation of a 168-Gene Expression Signature for Glioma Classification on a Single Molecule Counting Platform. Cancers, 2021, 13, 439.	1.7	4
6	Serum Levels of Inflammatory Proteins Are Associated With Peripheral Neuropathy in a Cross-Sectional Type-1 Diabetes Cohort. Frontiers in Immunology, 2021, 12, 654233.	2.2	7
7	Niacin Enhancement for Parkinsonâ€™s Disease: An Effectiveness Trial. Frontiers in Aging Neuroscience, 2021, 13, 667032.	1.7	21
8	Chronic Kidney Disease: Role of Diet for a Reduction in the Severity of the Disease. Nutrients, 2021, 13, 3277.	1.7	43
9	The 3p21.31 genetic locus promotes progression to type 1 diabetes through the CCR2/CCL2 pathway. Journal of Translational Autoimmunity, 2021, 4, 100127.	2.0	3
10	T1DMicro: A Clinical Risk Calculator for Type 1 Diabetes Related Microvascular Complications. International Journal of Environmental Research and Public Health, 2021, 18, 11094.	1.2	2
11	Niacin and Butyrate: Nutraceuticals Targeting Dysbiosis and Intestinal Permeability in Parkinsonâ€™s Disease. Nutrients, 2021, 13, 28.	1.7	23
12	Low-Dose Niacin Supplementation Improves Motor Function in US Veterans with Parkinsonâ€™s Disease: A Single-Center, Randomized, Placebo-Controlled Trial. Biomedicines, 2021, 9, 1881.	1.4	6
13	Niacin for Parkinson's disease. Clinical and Experimental Neuroimmunology, 2020, 11, 47-56.	0.5	9
14	Senescence-Associated Secretory Phenotype Determines Survival and Therapeutic Response in Cervical Cancer. Cancers, 2020, 12, 2899.	1.7	9
15	Comparative analysis of transcriptomic profile, histology, and IDH mutation for classification of gliomas. Scientific Reports, 2020, 10, 20651.	1.6	6
16	Better survival is observed in cervical cancer patients positive for specific anti-glycan antibodies and receiving brachytherapy. Gynecologic Oncology, 2020, 157, 181-187.	0.6	7
17	Cell-based high throughput screening identified a novel compound that promotes regulatory T cells and prevents autoimmune colitis. Biochemical Pharmacology, 2019, 169, 113618.	2.0	2
18	Niacin Ameliorates Neuro-Inflammation in Parkinsonâ€™s Disease via GPR109A. International Journal of Molecular Sciences, 2019, 20, 4559.	1.8	39

#	Article	IF	Citations
19	A combined score of clinical factors and serum proteins can predict time to recurrence in high grade serous ovarian cancer. Gynecologic Oncology, 2019, 152, 574-580.	0.6	23
20	Multiplex glycan bead array for high throughput and high content analyses of glycan binding proteins. Nature Communications, 2018, 9, 258.	5.8	66
21	Proteins of TNF-Î± and IL6 Pathways Are Elevated in Serum of Type-1 Diabetes Patients with Microalbuminuria. Frontiers in Immunology, 2018, 9, 154.	2.2	22
22	Sphingosine Toxicity in EAE and MS: Evidence for Ceramide Generation via Serine-Palmitoyltransferase Activation. Neurochemical Research, 2017, 42, 2755-2768.	1.6	32
23	IGF-Binding Proteins in Type-1 Diabetes Are More Severely Altered in the Presence of Complications. Frontiers in Endocrinology, 2016, 7, 2.	1.5	19
24	Luminex and Other Multiplex High Throughput Technologies for the Identification of, and Host Response to, Environmental Triggers of Type 1 Diabetes. BioMed Research International, 2015, 2015, 1-7.	0.9	16
25	Elevated Serum Levels of Soluble TNF Receptors and Adhesion Molecules Are Associated with Diabetic Retinopathy in Patients with Type-1 Diabetes. Mediators of Inflammation, 2015, 2015, 1-8.	1.4	47
26	Large-Scale Discovery and Validation Studies Demonstrate Significant Reductions in Circulating Levels of IL8, IL-1Ra, MCP-1, and MIP-1Î² in Patients With Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1179-E1187.	1.8	28
27	Twelve Serum Proteins Progressively Increase With Disease Stage in Squamous Cell Cervical Cancer Patients. International Journal of Gynecological Cancer, 2014, 24, 1085-1092.	1.2	22
28	Mycophenolic Acid Inhibits Migration and Invasion of Gastric Cancer Cells via Multiple Molecular Pathways. PLoS ONE, 2013, 8, e81702.	1.1	38
29	Over-expression of Stat5b confers protection against diabetes in the non-obese diabetic (NOD) mice via up-regulation of CD4+CD25+ regulatory T cells. Biochemical and Biophysical Research Communications, 2012, 424, 669-674.	1.0	8
30	Serum insulin-like growth factor binding protein 6 (IGFBP6) is increased in patients with type 1 diabetes and its complications. International Journal of Clinical and Experimental Medicine, 2012, 5, 229-37.	1.3	12
31	Chemokine (C-C Motif) Ligand 2 (CCL2) in Sera of Patients with Type 1 Diabetes and Diabetic Complications. PLoS ONE, 2011, 6, e17822.	1.1	27
32	Discovery and Validation of Serum Protein Changes in Type 1 Diabetes Patients Using High Throughput Two Dimensional Liquid Chromatography-Mass Spectrometry and Immunoassays. Molecular and Cellular Proteomics, 2011, 10, M111.012203.	2.5	63
33	Advances and challenges in biomarker development for type 1 diabetes prediction and prevention using â€˜omicâ€™ technologies. Expert Opinion on Medical Diagnostics, 2010, 4, 397-410.	1.6	7
34	Proteomic Technologies for the Discovery of Type 1 Diabetes Biomarkers. Journal of Diabetes Science and Technology, 2010, 4, 993-1002.	1.3	41
35	Cadmium reduces nitric oxide production by impairing phosphorylation of endothelial nitric oxide synthase. Biochemistry and Cell Biology, 2008, 86, 1-10.	0.9	54
36	IFIH1 polymorphisms are significantly associated with type 1 diabetes and IFIH1 gene expression in peripheral blood mononuclear cells. Human Molecular Genetics, 2008, 18, 358-365.	1.4	140

#	Article	IF	Citations
37	Extracellular High-Mobility Group Box 1 Acts as an Innate Immune Mediator to Enhance Autoimmune Progression and Diabetes Onset in NOD Mice. Diabetes, 2008, 57, 2118-2127.	0.3	101
38	Biomarkers for type 1 diabetes. International Journal of Clinical and Experimental Medicine, 2008, 1, 98-116.	1.3	27
39	The Autoimmune Regulator Directly Controls the Expression of Genes Critical for Thymic Epithelial Function. Journal of Immunology, 2007, 178, 7173-7180.	0.4	46
40	Assessing the utility of SELDI-TOF and model averaging for serum proteomic biomarker discovery. Proteomics, 2006, 6, 6405-6415.	1.3	33
41	Lack of correlation between the levels of soluble cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and the CT-60 genotypes. Journal of Autoimmune Diseases, 2005, 2, 8.	1.0	46
42	Mapping DNA-binding domains of the autoimmune regulator protein. Biochemical and Biophysical Research Communications, 2005, 327, 939-944.	1.0	46
43	A Mutant Stat5b with Weaker DNA Binding Affinity Defines a Key Defective Pathway in Nonobese Diabetic Mice. Journal of Biological Chemistry, 2004, 279, 11553-11561.	1.6	33
44	A functional variant of SUMO4, a new IÎºBÎ± modifier, is associated with type 1 diabetes. Nature Genetics, 2004, 36, 837-841.	9.4	369
45	Impaired E-cadherin expression in human spermatozoa in a male factor infertility subset signifies E-cadherin-mediated adhesion mechanisms operative in spermâ€“oolemma interactions. Biochemical and Biophysical Research Communications, 2004, 316, 903-909.	1.0	13
46	Acrosome reaction inducers impose alterations in repulsive strain and hydration barrier in human sperm membranes. IUBMB Life, 1998, 45, 227-235.	1.5	2
47	Selective degradation of serum proteins is likely responsible for the spurious differences in innate immunity proteins observed in a type 1 diabetes study. F1000Research, 0, 3, 237.	0.8	0